These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 9167946)
41. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma. Melillo RM; Cirafici AM; De Falco V; Bellantoni M; Chiappetta G; Fusco A; Carlomagno F; Picascia A; Tramontano D; Tallini G; Santoro M Am J Pathol; 2004 Aug; 165(2):511-21. PubMed ID: 15277225 [TBL] [Abstract][Full Text] [Related]
42. Gene rearrangement and Chernobyl related thyroid cancers. Santoro M; Thomas GA; Vecchio G; Williams GH; Fusco A; Chiappetta G; Pozcharskaya V; Bogdanova TI; Demidchik EP; Cherstvoy ED; Voscoboinik L; Tronko ND; Carss A; Bunnell H; Tonnachera M; Parma J; Dumont JE; Keller G; Höfler H; Williams ED Br J Cancer; 2000 Jan; 82(2):315-22. PubMed ID: 10646883 [TBL] [Abstract][Full Text] [Related]
43. Classical point mutations of RET, BRAF and RAS oncogenes are not shared in papillary and medullary thyroid cancer occurring simultaneously in the same gland. Ciampi R; Romei C; Pieruzzi L; Tacito A; Molinaro E; Agate L; Bottici V; Casella F; Ugolini C; Materazzi G; Basolo F; Elisei R J Endocrinol Invest; 2017 Jan; 40(1):55-62. PubMed ID: 27535135 [TBL] [Abstract][Full Text] [Related]
44. Familial non-medullary thyroid carcinoma (FNMTC): analysis of fPTC/PRN, NMTC1, MNG1 and TCO susceptibility loci and identification of somatic BRAF and RAS mutations. Cavaco BM; Batista PF; Martins C; Banito A; do Rosário F; Limbert E; Sobrinho LG; Leite V Endocr Relat Cancer; 2008 Mar; 15(1):207-15. PubMed ID: 18310288 [TBL] [Abstract][Full Text] [Related]
46. Genetics of follicular thyroid cancer. Farid NR; Zou M; Shi Y Endocrinol Metab Clin North Am; 1995 Dec; 24(4):865-83. PubMed ID: 8608782 [TBL] [Abstract][Full Text] [Related]
47. Morphological aspects of thyroid cancer and tumour prognosis. Williams D J Endocrinol Invest; 1995 Feb; 18(2):153-4. PubMed ID: 7629386 [No Abstract] [Full Text] [Related]
49. Detection of RET/PTC, TRK and BRAF mutations in preoperative diagnosis of thyroid nodules with indeterminate cytological findings. Sapio MR; Posca D; Raggioli A; Guerra A; Marotta V; Deandrea M; Motta M; Limone PP; Troncone G; Caleo A; Rossi G; Fenzi G; Vitale M Clin Endocrinol (Oxf); 2007 May; 66(5):678-83. PubMed ID: 17381488 [TBL] [Abstract][Full Text] [Related]
50. New insights in thyroid follicular cell biology and its impact in thyroid cancer therapy. Riesco-Eizaguirre G; Santisteban P Endocr Relat Cancer; 2007 Dec; 14(4):957-77. PubMed ID: 18045949 [TBL] [Abstract][Full Text] [Related]
51. Point mutations of ras oncogenes are an early event in thyroid tumorigenesis. Namba H; Rubin SA; Fagin JA Mol Endocrinol; 1990 Oct; 4(10):1474-9. PubMed ID: 2283998 [TBL] [Abstract][Full Text] [Related]
52. Multiple genetic alterations in papillary thyroid cancer are associated with younger age at presentation. Moses W; Weng J; Khanafshar E; Duh QY; Clark OH; Kebebew E J Surg Res; 2010 May; 160(2):179-83. PubMed ID: 19765726 [TBL] [Abstract][Full Text] [Related]
53. High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis. Lemoine NR; Mayall ES; Wyllie FS; Williams ED; Goyns M; Stringer B; Wynford-Thomas D Oncogene; 1989 Feb; 4(2):159-64. PubMed ID: 2648253 [TBL] [Abstract][Full Text] [Related]
54. RET rearrangements and BRAF mutation in undifferentiated thyroid carcinomas having papillary carcinoma components. Mochizuki K; Kondo T; Nakazawa T; Iwashina M; Kawasaki T; Nakamura N; Yamane T; Murata S; Ito K; Kameyama K; Kobayashi M; Katoh R Histopathology; 2010 Sep; 57(3):444-50. PubMed ID: 20840674 [TBL] [Abstract][Full Text] [Related]
55. [BRAFV599E mutation and RET/PTC rearrangements in papillary thyroid carcinoma]. Zhu XL; Zhou XY; Zhu XZ Zhonghua Bing Li Xue Za Zhi; 2005 May; 34(5):270-4. PubMed ID: 16181547 [TBL] [Abstract][Full Text] [Related]
56. The C allele of the GNB3 C825T polymorphism of the G protein beta3-subunit is associated with an increased risk for the development of oncocytic thyroid tumours. Sheu SY; Handke S; Bröcker-Preuss M; Görges R; Frey UH; Ensinger C; Ofner D; Farid NR; Siffert W; Schmid KW J Pathol; 2007 Jan; 211(1):60-6. PubMed ID: 17136758 [TBL] [Abstract][Full Text] [Related]
57. Pathology and genetics of thyroid carcinoma. DeLellis RA J Surg Oncol; 2006 Dec; 94(8):662-9. PubMed ID: 17131411 [TBL] [Abstract][Full Text] [Related]
58. An overview of molecular abnormalities leading to thyroid carcinogenesis: a 1993 perspective. Gagel RF Stem Cells; 1997; 15 Suppl 2():7-13. PubMed ID: 9368282 [TBL] [Abstract][Full Text] [Related]
59. Detection of activated ras oncogenes in human thyroid carcinomas. Suárez HG; Du Villard JA; Caillou B; Schlumberger M; Tubiana M; Parmentier C; Monier R Oncogene; 1988 Apr; 2(4):403-6. PubMed ID: 3283656 [TBL] [Abstract][Full Text] [Related]
60. The epidemiology and etiology of differentiated thyroid carcinoma. Busnardo B; De Vido D Biomed Pharmacother; 2000 Jul; 54(6):322-6. PubMed ID: 10989966 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]